Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. (CVKD): 3 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.5 months
D/E 0.59 · 0% dilution
Lead: Phase 3
3 candidates
N/A
0 buys · 13 sells (180d)
A transparent, data-derived signal for Cadrenal Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$9.9M
Cash
$2.3M
Quarterly Burn
$3.0M
Runway
2.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cad-1005 | Phase 3 |
| frunexian | Phase 2 |
| tecarfarin | Phase 2/Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$647K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 90,402 | $463K |
| geode capital management, llc | 21,626 | $111K |
| vanguard fiduciary trust co | 8,311 | $43K |
| blackrock, inc. | 5,496 | $28K |
| osaic holdings, inc. | 300 | $2K |
| morgan stanley | 100 | $512 |
| wells fargo & company/mn | 99 | $507 |
| archer investment corp | 35 | $179 |
| ifp advisors, inc | 30 | $154 |
| ubs group ag | 3 | $15 |
Showing top 10 of 12 institutional holders of Cadrenal Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Cadrenal Therapeutics, Inc.'s pipeline?
Cadrenal Therapeutics, Inc. (CVKD) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cadrenal Therapeutics, Inc.'s lead drug candidate?
Cadrenal Therapeutics, Inc.'s most advanced tracked candidate is cad-1005 (Phase 3) for heparin-induced thrombocytopenia ("HIT").
What is Cadrenal Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cadrenal Therapeutics, Inc. has approximately 2.5 months of cash runway.
What is Cadrenal Therapeutics, Inc.'s market capitalization?
Cadrenal Therapeutics, Inc.'s market capitalization is approximately $9.9M.
Who is the CEO of Cadrenal Therapeutics, Inc.?
Mr. Quang X. Pham is the chief executive officer of Cadrenal Therapeutics, Inc. (CVKD).
Get the full picture on Cadrenal Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.